John McConville

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Diseases of the neuromuscular junction
    John McConville
    Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Curr Opin Pharmacol 2:296-301. 2002
  2. ncbi request reprint Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets
    Angela Vincent
    Department of Clinical Neurology, University of Oxford, UK
    Lancet Neurol 2:99-106. 2003
  3. ncbi request reprint Antibodies in myasthenia gravis and related disorders
    Angela Vincent
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Ann N Y Acad Sci 998:324-35. 2003
  4. ncbi request reprint Detection and characterization of MuSK antibodies in seronegative myasthenia gravis
    John McConville
    Weatherall Institute of Molecular Medicine and Department of Clinical Neurology, Oxford, UK
    Ann Neurol 55:580-4. 2004
  5. ncbi request reprint Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis
    Ioannis Roxanis
    Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    J Neuroimmunol 125:185-97. 2002
  6. ncbi request reprint Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients
    Lan Zhou
    Neuromuscular Unit, Department of Neurology, Johns Hopkins School of Medicine, Meyer Building 5 119, 600 North Wolfe Street, Baltimore, Maryland 21287 7519, USA
    Muscle Nerve 30:55-60. 2004
  7. ncbi request reprint Seronegative myasthenia gravis
    Angela Vincent
    Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
    Semin Neurol 24:125-33. 2004
  8. ncbi request reprint Is "seronegative" MG explained by autoantibodies to MuSK?
    Angela C Vincent
    Neurology 64:399; author reply 399. 2005

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Diseases of the neuromuscular junction
    John McConville
    Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Curr Opin Pharmacol 2:296-301. 2002
    ..This is proving relevant to seronegative myasthenia gravis, with the discovery of anti-MuSK antibodies, and to a type of congenital myasthenic syndrome, in which acetylcholine receptor deficiency is due to mutations in rapsyn...
  2. ncbi request reprint Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets
    Angela Vincent
    Department of Clinical Neurology, University of Oxford, UK
    Lancet Neurol 2:99-106. 2003
    ..Moreover, muscle wasting may be present, which prevents complete response to these therapies...
  3. ncbi request reprint Antibodies in myasthenia gravis and related disorders
    Angela Vincent
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Ann N Y Acad Sci 998:324-35. 2003
    ..These antibodies are not found in AChR antibody-positive MG and are predominantly IgG4. MuSK antibody positivity appears to be associated with more severe bulbar disease that can be difficult to treat effectively...
  4. ncbi request reprint Detection and characterization of MuSK antibodies in seronegative myasthenia gravis
    John McConville
    Weatherall Institute of Molecular Medicine and Department of Clinical Neurology, Oxford, UK
    Ann Neurol 55:580-4. 2004
    ..They bind to the extracellular Ig-like domains of soluble or native MuSK. Surprisingly they are predominantly in the IgG4 subclass. MuSK-antibody associated MG may be different in etiological and pathological mechanisms...
  5. ncbi request reprint Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis
    Ioannis Roxanis
    Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    J Neuroimmunol 125:185-97. 2002
    ..As autoantibodies became detectable, myoid cell involvement apparently progressed. Our unifying hypothesis--that an early autoantibody attack on myoid cells provokes local GC formation--helps to resolve many puzzles...
  6. ncbi request reprint Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients
    Lan Zhou
    Neuromuscular Unit, Department of Neurology, Johns Hopkins School of Medicine, Meyer Building 5 119, 600 North Wolfe Street, Baltimore, Maryland 21287 7519, USA
    Muscle Nerve 30:55-60. 2004
    ..Although the distribution of weakness differs somewhat depending on whether MuSK antibodies are present, responses to anticholinesterase and immunosuppressive treatments are similar...
  7. ncbi request reprint Seronegative myasthenia gravis
    Angela Vincent
    Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
    Semin Neurol 24:125-33. 2004
    ..MuSK antibody-positive patients may also differ in the distribution of their electrophysiological abnormalities and their responses to treatments...
  8. ncbi request reprint Is "seronegative" MG explained by autoantibodies to MuSK?
    Angela C Vincent
    Neurology 64:399; author reply 399. 2005